ArticleCNS drugs2012
Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
Article in CNS drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 5 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Lamotrigine add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2023Pooled it
- Effects of generic exchange of solid oral dosage forms in neurological disorders: a systematic review.International journal of clinical pharmacy · 2020Pooled it
- Lamotrigine add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2020Pooled it
- Lamotrigine add-on for drug-resistant partial epilepsy.The Cochrane database of systematic reviews · 2016Pooled it
- The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review.Applied health economics and health policy · 2015Pooled it
- Attitudes towards the switching of anti-epileptic medications in pharmacies: the patients' perspective.Postepy psychiatrii neurologii · 2023Article
- Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.Pharmacotherapy · 2017Article
- Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.Drug design, development and therapy · 2017Article
- Causal inference as an emerging statistical approach in neurology: an example for epilepsy in the elderly.Clinical epidemiology · 2017Review
- Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database.Pragmatic and observational research · 2017Article
- Observational
- Distribution and trends in outpatient utilization of generic versus brand name psychopharmaceuticals during a ten-year period in Croatia.BMC health services research · 2014Article
- Rational use of generic psychotropic drugs.CNS drugs · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundControversy exists about the safety of substituting generic antiepileptic drugs (AEDs). Lamotrigine, the prototypical newer AED, is often used for psychiatric and neurological conditions other than epilepsy. The safety of generic substitution of lamotrigine in diverse populations of AED users is unclear.
objectiveThe objective of this study was to evaluate potential associations between generic substitution of lamotrigine and adverse consequences in a population of diverse users of this drug. STUDY
designThis study was a retrospective cohort-crossover design using state Medicaid claims data from July 2006 through June 2009.
methodsSubjects were included in the cohort if they converted from brand to generic lamotrigine and had 2 years of lamotrigine use prior to conversion. The frequency of emergency department (ED) visits, hospitalizations and condition-specific ED visits or hospitalizations were recorded in the 60 days immediately following the conversion to generic lamotrigine, then compared with the incidence of the same events during a randomly selected time period indexed to one of the patient's past refills of branded lamotrigine. Multivariate conditional logistic regression was used to quantify the association between generic conversion and health services utilization while controlling for changes in lamotrigine dose and concurrent drug use.
resultsOf the 616 unique subjects included in this analysis, epilepsy was the most common diagnosis (41%), followed by bipolar disorder (32%), pain (30%) and migraine (18%). Conversion to generic lamotrigine was not associated with a statistically significant increase in the odds of an ED visit (adjusted odds ratio [AOR] = 1.35; 95% confidence interval [CI] 0.92, 1.97), hospitalization (AOR = 1.21; 95% CI 0.60, 2.50) or condition-specific encounter (AOR 1.75; 95 CI 0.87, 3.51).
conclusionsA statistically significant increase in ED visits, hospitalizations or condition-specific encounters was not observed following the switch from brand to generic lamotrigine, although a type II error cannot be ruled out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.